



Northern California Lab Medical Director: Brad Lewis, MD 2023 Eighth Street, Berkeley, CA 94710 New Orleans Lab (**local samples can be sent directly) Medical Director: Gloria Coker, MD 8721 Oak Street, New Orleans, LA 70118

		Phone: (510) 839-5600 / Fax: (510) 83		:: (504) 866-7091	
PATIENT HISTORY			SUBMITTING FACILITY		
Patient's Name: (Last, First, M.I.) *		Specimen Date and Time:*	Client Account #: Facility Name and Address:*	*= REQUIRED	
Sex:* DOB:*	MRN:*	Ordering Provider: (Last, First)*			
Platelet Count(K/µL), aPTT(sec.), PT(sec.), INR Hematocrit(%), Bleeding History(Y/N), Clotting History(Y/N)					
☐ Patient is anticoagulated☐ Patient is on antiplatelet medicatio	Please specify: ☐ coumadin ☐ LMWH [_UFHapixabanrivaroxaban	Phone:*	Fax for results:*	
☐ Patient is on Hemlibra therapy	dabigatran fondaparinu: Aspirin Plavix B		☐ STAT ☐ Sponsored Testin	g □ Insurance Billing (please complete form)	
PANEL TESTING			GENETIC PANEL TESTING (STAT <2 DAYS)		
 □ LA Coag Antiphospholipid Antibody Panel (PT/INR, aPTT, aPTT-LA, ACL, Beta-2 GPI and PS Antibodies- IgG, IgM, IgA) □ Do not reflex to LA Panel □ Antiphospholipid Syndrome Criteria Panel (aPTT-LA, dRVVT, Anticardiolipin) 			□ ADAMTS13 Gene Sequencing (1 genes)□ Alport Syndrome Genetic Panel (3 genes)		
Beta-2 Glycoprotein I Antib	oodies- IgG, IgM, IgA) 🗆 Do	not reflex to LA Panel	al los delletic Fai		
☐ Heparin Antibody Panel (TAT <24 Hrs)				hy Genetic Panel (6 genes)	
(Immunologic [ELISA] and Functional [washed-platelet Heparin-induced Platelet Activation] □ Hypercoagulability / Thrombophilia Panel (STAT <24 Hrs) (Please visit our website for complete testing algorithm)			 □ Dysfibrinogenemia Genetic Panel (3 genes, FGA, FGB, FGG) □ HLH Genetic Panel 3.0 (32 genes) □ Reflex to HLH Extended Panel 		
□ Lupus Anticoagulant Screen (ACL, dRVVT, aPTT-LA) □ Do not reflex to LA Panel □ Panel (ACL, aPTT Mixing Study, Lupus Anticoagulant Index, dRVVT, Thrombin Time and PT/II					
(DILLIA CINALED CIETI ACCUETI ICT DECINO)			□ PlateletGenex™ Tl	hrombocytopenia Panel (26 genes) Disease (PKD) Genetic Panel (2 genes)	
□ Prolonged aPTT / PT Evaluation Work-up (STAT <24 Hrs) (Please visit our website for complete testing algorithm)			□ TMA-Complete™ Genetic Panel 2.0 (20 genes)		
□ von Willebrand Factor Profile □ Do not reflex to VWF:Multimer (STAT <24 Hrs) (Factor VIII Activity, VWF:Antigen, VWF:RCo, aPTT and if indicated, VWF:Multimer)			-	ng Genetic Panel (29 genes) Genetic Panel (VWF and GP1BA)	
TEST LIST	-	·			
□ Factor V (5) Leiden G □ Factor VIII (8) Chrom □ Factor VIII (8) Gene Seque □ Factor IX (9) Gene Seque □ Factor XIII (13) Activity □ Fibrinogen Activity an □ Hemlibra-specific Fa □ Heparin Antibody Con	reflexes to Inhib and Ab)* tivity, Inhibitor and Antibor quencing dy vity and/or □ Antigen evel tein I - IgG, IgM and IgA) Time ased) □ test all factors XI (11) □ XII (12) ed) □ test all factors □ VII (7) □ X (10) Gene Mutation togenic Activity (bovine uencing and Inversions Assa encing and/or □ Gene Sequencin and/or □ Antigen ctor VIII (8) Activity* nfirmation (wp-HIPA)	* Hexagonal Phosph dy) Homocysteine HPP/OI Genetic Pa Inhibitor to Factor(s VIII (8) IX (9) III (2) V (5) Inhibitor to F8 (Hemli IL-18 Level Mixing Study (aPTT) MIXING Study (PT) MIXING HERE Plasminogen Activ Plasminogen Gene Plasminogen Gene Plasminogen Gene Platelet Aggregatio Platelet Aggregatio Platelet Aggregatio Platelet Electron M	nel (Hypophosphatasia) s) (Bethesda Units) □ XI (11) □ XII (12) □ VII (7) □ X (10) bra-specific Nijmegen Bethesda) ** - reflex to incubated mix d/or □ A1298C) Mutations - up itive Reagent) ity and/or □ Autoantibody Sequencing r □ PAI-1 Gene Sequence on Study (Comprehensive) ** iule Release Study ** on - ASA (Aspirin Sensitivity) ** on - RIPA (Ristocetin-induced) **	□ Protein C Activity and/or □ Antigen □ Protein S Activity □ Protein S Antigen [Free] and/or □ [Total] □ Prothrombin Gene Mutation □ Prothrombin Time □ Reflex to work-up □ PSAntibody (phosphotidylserine; IgG, IgM)** □ PS/PTAntibody (IgG, IgM) ** □ Rivaroxaban (Xarelto) Level □ dRVVT (dilute Russell Viper Venom Time) □ Soluble Complement 5b-9 (sC5b-9) □ Soluble IL-2 Receptor Alpha □ serum □ EDTA plasma □ Thrombin Time - TCT (confirmed w/PS) □ Thrombin-Antithrombin (TAT) □ VWF Activity (Ristocetin cofactor) □ VWF Activity (GP1BM-based) □ VWF Multimer (WF:Multimer) □ wp-HIPA (washed-platelet Heparin-induced Platelet Activation Assay) Misc	
□ Heparin Antibody Ref		4)**			
ADDITIONAL INFORM	ATION		MACHAON USE ONLY		

Patients with insurance coverage other than Medicare are considered out-of-network. Medicare patients must sign an ABN, downloaded from the Machaon Diagnostics website. Insurance billing services are provided to contracted clients only under a current Insurance Billing Contract. Samples originating from NY-state for genetic testing are required to have a signed genetic consent document on file prior to testing. Note: NGS panels are updated periodically to reflect the

Temperature indicator acceptable (choose one): Yes

Specimen type received:_ Aliquots:_ Specimen type received:_ Aliquots:_ Tech initials: __ ____ Received stamp: _

No

N/A